Driving the mission
The Coherence team operates where neurotechnology, biology, and AI converge. We create systems that decode the body’s bioelectronic language and turn it into actionable insight, enabling precise, adaptive interventions that disrupt cancer at its source.
Our story
Coherence is the brainchild of our co-founders, Dr. Ben Woodington and Dr. Elise Jenkins, who met in 2018 while carrying out research across the fields of neuroengineering and neuro-oncology at the University of Cambridge.
They believe that the world is at an inflection point: that the miniaturization of neuroelectronics, a step change in compute and AI, and new powering methods are going to dramatically extend the use of therapeutic BCI technologies. Bringing them into wider usage across hundreds of diseases and disorders.
“Treating and monitoring my patients, in real time, will revolutionise my practice”
Dr Ryan Mathew [Neurosurgeon]
Prof at Leeds, Principal Investigator for NIHR clinical trials
2022
Coherence is born
2023
Develops first implants to measure and modulate brain tumors in real time
2023
Discovered first neural biomarkers of cancer progression and aggression
2023
First safety study of SOMA-1
2024
Launched first pipeline indication in pancreatic cancer
2025
Expanded company to US, launching SF office and in vivo facility for pipeline expansion
Leadership
.png)
Ben has worked from early stage, translational neurotechnology and BCI research at University of Cambridge to new product innovation, industrialisation, and partnerships across multiple medtech companies including Philips Healthcare.
Ben Woodington, PhD
Co-founder & CEO
.png)
Elise’s research background is in bioelectronics and cancer neurotechnology at the University of Cambridge. She previously led technical teams at Siemens. In 2024 she was awarded Forbes 30u30 for her part in building Coherence
Elise Jenkins, PhD
Co-founder & CTO
.png)
José is a mechanical engineer by training. He was previously Head of Engineering at Iota Biosciences. He has brought multiple technologies to clinical via Abbott and Setpoint Medical.
José Lepe
VP Engineering
.png)
Jason is a neuroscientist by training who previously led translational efforts for Galvani Bioelectronics. Prior to that he focused on neuro research at Pfizer.
Jason Mirada, PhD
Director Translation
Spotlight
.png)
Maekele Gebrekidana
Pricipal Engineer
.png)
Carolina Silveira, PhD
Quality and Regulatory Specialist
Isabel Dzuiba
Engineer II
.png)
Jake Stroud, PhD
Data & AI Lead
Advisory team
.png)
Prof George Malliaras, FRS
Prof of Bioelectronics at Cambridge University (fmr. IBM, Cornell)
.png)
Dr Ryan Matthew , PhD, FRCS
Neurosurgeon, Prof at Leeds, Principal Investigator for NIHR clinical trials
.png)
Prof Anne Vanhoestenburge
Prof of Implantable Medical Devices & Director of MAISI institute
.png)
Ryan Neely, PhD
VP Science, Elemind (fmr. Iota, Known Medicine)
Dr Andrew Morokoff
A/Prof Surgery Royal Melbourne Hospital, Clinical BCI pioneer
Brought to you by world-leading researchers, engineers, and scientists united by our mission.
